Very high levels of anti–citrullinated protein antibodies are associated with HLA–DRB1*15 non–shared epitope allele in patients with rheumatoid arthritis
Open Access
- 3 February 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (7) , 2078-2084
Abstract
Objective: Production of anti–citrullinated protein antibodies (ACPAs) is an important biomarker for rheumatoid arthritis (RA). We undertook this study to determine whether genetic factors (HLA—DRB1 alleles) are associated with extreme ACPA levels in individuals with ACPA‐positive RA, and to ascertain whether there are any phenotypic characteristics associated with these subgroups of RA.Methods: HLA–DRB1 allelic groups were genotyped in 1,073 ACPA‐positive RA patients from the Swedish Epidemiological Investigation of Rheumatoid Arthritis study. We found that 283 patients (26.4%) had high ACPA levels (defined as >1,500 units/ml using the Euro‐Diagnostica anti‐CCP2 test), while the rest of the patients had moderate ACPA levels and served as the comparison group. A replication group consisted of 235 RA patients.Results: No significant differences in baseline disease activity were observed between patients with high and those with moderate ACPA levels. However, the HLA–DRB1*15 allele was associated with high ACPA levels (P = 0.0002). A similar trend was detected in HLA–DRB1*15–positive patients in the replication cohort, with meta‐analysis of the discovery and replication cohorts demonstrating an overall effect of HLA–DRB1*15 on development of high ACPA levels in both the discovery and replication cohorts (P < 0.0001 by Mantel‐Haenszel test with a fixed‐effects model).Conclusion: Our data indicate that HLA–DRB1*15 may promote the production of high ACPA levels. Due to the high value of ACPA level scores in the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA, the presence of HLA–DRB1*15 may, at least in part, contribute to fulfilling the criteria for RA. This illustrates the complex nature of the genetic regulation of ACPA levels. Additional mechanistic studies of the regulation of ACPAs and ACPA‐positive RA are pending.Keywords
This publication has 28 references indexed in Scilit:
- A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt studyAnnals of the Rheumatic Diseases, 2010
- Rheumatoid arthritisThe Lancet, 2009
- Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2009
- The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritisArthritis & Rheumatism, 2006
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progressionAnnals of the Rheumatic Diseases, 2005
- Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteinsArthritis & Rheumatism, 2005
- Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestationsAnnals of the Rheumatic Diseases, 2004
- A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritisArthritis Research & Therapy, 2004
- Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.Journal of Clinical Investigation, 1998